BELLEVILLE, ON, April 14, 2014 /PRNewswire/ – Bioniche Life Sciences Inc. (TSX:
BNC) today announced that its shareholders have voted in favour of the
sale of the Company’s Animal Health business to V toquinol SA.

At a Special Meeting of Shareholders held this morning in Toronto, 39.4%
of the issued and outstanding shares were voted, with 97.4% of those
voting in favour of the sale transaction.

The transaction is expected to close tomorrow.

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a clinical stage Canadian
biopharmaceutical company focused on the discovery, development,
manufacturing, and marketing of proprietary and innovative therapies
for the global human health market. The Company’s primary goal is to
develop and commercialize products that advance human health and increase shareholder value. For more
information, please visit www.Bioniche.com.

Except for historical information, this news release may contain
forward-looking statements that reflect the Company’s current
expectation regarding future events. These forward-looking statements
involve risk and uncertainties, which may cause, but are not limited
to, changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact
of competitive products and pricing, new product development,
uncertainties related to the regulatory approval process, and other
risks detailed from time to time in the Company’s ongoing quarterly and
annual reporting.

SOURCE Bioniche Life Sciences Inc.